Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?

Blood Cancer J. 2023 Dec 21;13(1):194. doi: 10.1038/s41408-023-00959-8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Mutation
  • Neoplasm Recurrence, Local* / genetics
  • Nuclear Proteins / genetics
  • Nucleophosmin
  • Prognosis

Substances

  • Nuclear Proteins
  • Nucleophosmin